News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

Peregrine Pharmaceuticals Extends Its Agreement for the Development of Tumor Necrosis Therapy -TNT- in the People`s Republic of China (Business Wire)...The application for regulatory approval was based upon clinical trials conducted at multiple centers in China for the past five years involving patients with various types of cancer such as lung, colorectal, brain, gastric, liver and sarcoma.......Collateral targeting agents are designed to bind to elements of tumors that are common to all solid tumors or are the product of tumor growth....- May 23 11:02 AM ET


IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/bw/010523/0253.html


(Everything below this line is from VirtualTrials.com!)

Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740